echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > The future of biased IL-2 is uncertain, and Nektar seeks to merge

    The future of biased IL-2 is uncertain, and Nektar seeks to merge

    • Last Update: 2022-10-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com


    After failing three consecutive IL-2 clinical trials, Nektar began seeking concorposion
    .
    PureTech Health said in a statement that it had exchanged non-binding indicative proposals with Nektar Therapeutics for a possible merger, including an offer to acquire PureTech's share capital
    .
    Founded in 1990, Nektar Therapeutics is the leading player
    in the IL-2 space.
    The debut of the IL-2-biased activator developed by Nektar at the 2017 SITC conference has attracted widespread attention from the
    industry.
    In melanoma, NKTR-214 and PD1 achieved 64% (7/11) ORR, a stunning figure that not only led to a $3.
    6 billion partnership with BMS, but also drove Nektar's stock price up
    multiple times.
    NKTR-214 is an IL-2-biased activator that passes through the PEG-based form of 6 mers, and after injection into the body, 6 PEG modifications gradually fall off, forming the forms of active 2-PEG and 1-PEG
    .
    PEGization on the one hand hinders binding to IL-2Rα, biased activation of Teff cells; On the other hand, PGE also effectively improves the half-life of NKTR-214
    .
    The FDA awarded it the title
    of breakthrough therapy in July 2019.
    At that time, whether it was the amazing clinical data or the huge bet of BMS, everyone was full of expectations
    for NKTR-214.
    But the prospects for NKTR-214 development soon began to dim
    in the declining clinical efficacy.
    In the expanded PIVOT-02 clinical study disclosed at the 2018 ASCO conference, ORR in melanoma patients has been reduced to 52.
    6%.

    After advancing to phase III clinical, NKTR-214 is still difficult to reflect clinical advantages
    .
    On March 14, 2022, NKTR-214+Opdivo Phase III clinical PIVOT IO-001 suddenly failed
    .
    After analysis, NKTR-214+ Opdivo combination therapy did not provide additional clinical benefit over Opdivo monotherapy, the primary clinical endpoints such as PFS and ORR were not met, and there was no statistical difference
    in overall survival time OS.
    On April 14, based on the clinical advance analysis of kidney cancer stage III and bladder cancer stage II, the results were not as expected, and finally BMS announced the termination of cooperation, and all clinical studies of IL-2 combined + Opdivo treatment were also terminated
    .
    The rupture of the partnership with BMS also triggered a major layoff in Nektar
    .
    A month after the announcement, Nektar Therapeutics announced a 70 percent layoff, and the company's chief medical officer, Dimitry Nuyten, MD, and chief commercial officer, John Northcott
    , stepped down.
    In addition, the company slashed its product pipeline to shift its focus to two other clinical-stage assets
    .
    The market reacted very differently to the news about the merger of the two companies, with PureTech's shares on both the NASDAQ and London Stock Exchange falling, while Nektar's shares rose
    slightly.

    References:

    https://endpts.
    com/rising-from-the-il-2-ashes-and-drastic-reorg-nektar-in-merger-talks-with-puretech/


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.